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ABSTRACT
Loss of E-cadherin-mediated adhesion is an important step in the 
progression of many carcinomas. In model systems, it has been shown that 
cadherin function requires not only proper E-cadherin expression but also 
its linkage to the cytoskeleton through catenins. Hence, defects in catenins 
may cause defective E-cadhcrin function, and catenins as well as E- 
cadherin might constitute prognostic indicators. Here, we extend our 
previous study on E-cadherin in bladder cancer (Cancer Res., 53: 3241- 
3245, 1993). We have evaluated the expression of E-cadherin-associated 
cytoplasmic molecules (a-, J3-, and y-catenins and pl20tos) to clarify 
whether or not the pattern of their expression could provide additional 
prognostic information beyond that from E-cadherin alone. Forty-eight 
frozen bladder tumor specimens and 9 samples of normal urothelium 
were studied by imimniohistochenrnstry. A discrepancy between the E- 
cadherin and catenin expression pattern was seen in 20.8% of cases. 
Abnormal expression of each molecule is significantly correlated with 
tumor grade (P < 0,01) and stage (P < 0.01). Reduced expression of all of 
the molecules correlates with poor survival (P < 0.01 for each variable). 
Proportional hazard regression analysis showed that /3-catenin, E-cad­
herin, and a-catenin have strong predictive value, whereas plakoglobin 
and pl2Qcas haye a somewhat lower predictive value. Within patients with 
invasive tumors, those with a normal staining for either E-cadherin, 
a-catenin, or /3-catenin show a trend toward better survival. However, the 
difference in survival is significant only for E-cadherin (P < 0.05). Thus, 
/3-catenin, E-cadherin, and a-catenin have similar prognostic values. 
Therefore, from a practical point of view, the expression of any of these 
proteins can be of prognostic value for patients with bladder cancer.
homotypic calcium-dependent intercellular adhesion. Several reports 
have indicated that E-cadherin, the epithelial-specific cadherin, is a 
key molecule for the maintenance of epithelial integrity and polarized 
function, and that the reduction of E-cadherin-mediated cell-cell ad­
hesion favors the dispersion of cancer cells (7, 8). Indeed, for most 
carcinoma types, decreased E-cadherin immunoreactivity correlates 
with a lack of differentiation and aggressiveness of the tumors. In this 
regard, our previous study on bladder cancer revealed the potential 
usefulness of E-cadherin immunohistochemistry as a prognostic 
marker (9).
Cadherins are complexed via their cytoplasmic domain with a set of 
molecules termed catenins, which link cadherins to the actin-based 
cytoskeleton. Proper linkage to the cytoskeleton is indispensable for 
E-cadherin function (10-12), Recently, studies on esophageal, stom­
ach, and breast cancers have suggested that assessment of «-catenin 
expression by immunohistochemistry might be a better prognostic 
factor than E-cadherin (13-15). As already mentioned, we have pre­
viously reported that reduced expression of E-cadherin is significantly 
associated with poor prognosis in patients with bladder carcinomas. In 
this paper, we extend our previous observation by comparing E- 
cadherin expression with catenin expression to clarify whether or not 
the expression pattern of catenins could provide additional prognostic 
value over E-cadherin alone in human bladder cancers. Furthermore, 
we have also studied the expression of another member of the /3-cate- 
nin/plakoglobin family, pl20cav, that was also recently shown to 
coimmunoprecipitate with E-cadherin (16).
INTRODUCTION
Transitional cell carcinoma of the urinary bladder comprises a 
spectrum of diseases with diverse natural histories. Seventy to 80% of 
these tumors present as superficial lesions that recur in 30-90% of the 
patients (1, 2). Fifteen to 20% of these recurrences become invasive 
and/or metastatic (3). Patients with invasive carcinomas are usually 
treated by radical cystectomy. However, metastatic disease appears 
after surgery in approximately 50% of the cases (4-6), Adjuvant 
therapy, including chemotherapy and radiotherapy, is under investi­
gation and shows encouraging results. Therefore, it is important to 
identify patients who might benefit from surgery with or without 
adjuvant therapy.
To invade the surrounding tissues and metastasize to distant organs, 
cancer cells have to detach from the primary lesion as an initial step. 
This involves disruption of normal cell-cell adhesion in epithelial 
tissues. In this respect, analysis of the molecular basis of cancer cell 
detachment is an important aspect of the study of cancer progression. 
Cadherins are a family of transmembrane glycoproteins involved in
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MATERIALS AND METHODS
Twenty-two superficial and 26 invasive bladder cancer specimens were 
included in this study. The male:female ratio of the patients was 39:9, and the 
age ranged from 42-88 years, with an average of 66.5 years. Tumor grade 1:2:3 
ratio was 5:21:22. The patients’ profiles are detailed in Table 1. Normal 
urothelium was obtained from five normal ureters from patients with renal cell 
carcinoma and four bladder samples from patients with nonurothelial tumors.
Antibodies used were HECD-1 (dilution 1:20) for E-cadherin (Takava), 
anti-/3-catenin (1:400) and anti-ppl20 (1:200) from Transduction Laboratories, 
and PG5.1 (1:10) for plakoglobin (Progen Biotechnik GmbH). For a-catenin 
staining, we developed a polyclonal mouse antiserum (used at the dilution 
1:1000). For this, we cloned nucleotides 454-1981 of human a-catenin cDNA 
(a kind gift from Dr. W. B. Isaacs, Johns Hopkins Hospital, Baltimore, MD) 
into the pRP265 plasmid. The a-catenin/glutathione 5-transferase fusion pro­
tein was purified and used as an antigen. The serum of one BALB/c female 
mouse after the second boost was used in this study. Before use, the antiserum 
was checked by Western blotting and found to recognize a single M T 102,000 
band comigrating with a-catenin (data not shown). Four-fAm frozen sections 
were fixed in 3% paraformaldehyde and then permeabilized in 0.2% Triton 
X-100 in PBS. Immunohistochemistry was performed using biotinylated sec­
ondary antibodies (1:200) and streptavidin biotin peroxidase complex (1:100) 
from Amersham.
Evaluation of the staining was carried out by three independent observers 
(T. S., P. P. B., and L. A. G.) without prior knowledge of the tumor stage and 
patient profile. If the staining pattern in cancer samples was similar to that in 
normal urothelium (i.e., staining at virtually all intercellular borders) it was 
evaluated as normal. Abnormal staining was divided into negative (i.e., com­
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Table l Cafeums and E-cadherin staining, c Unie ai and paihological üauijor each patient
Case
Age
(yr) Sex
Pathologie aln Expression patten/7
T reatment1"
Recurrence after Survival
Stage Grade a ß y pl20 E-cad TUR (mo) (mo) A/D‘7
1 42 F A I< 2 N N N N H TUR,MMC,BCG pTa,Gl,8m 60 < A
2 88 M A 2 N N N N H TURtMMC No 52 D
3 65 M 2< 3 H H H ( - ) M TUR,Cx Cx 60 < A
4 82 F 4 2 N H H H H TUR Invasive 5 D
5 81 M 2 2 N N N N N TUR Invasive 9 D
6 86 M 1 2 N N N N N TUR,MMC pTa,G2,l 1m 60< A
7 77 M A 1<2 N N N N N TUR No 31 D
8 73 M 3 3 H H H H H TUR Invasive 9 D
9 64 M 1 1 N N N N N TUR pTa,G2,4m 60< A
10 73 F 3 3 ( - ) H ( - ) H ( - ) TUR,rad Invasive 2 D
11 63 M 3 3 (“ ) ( - ) (“ ) ( - ) ( - ) TUR.rad Invasive 5 D
12 70 M 2 3 (~ ) ( - ) ( - ) ( - ) H TUR,Cx Cx 3 D
13 76 M 1 2 H H H H N TUR,rad Invasive 9 D
14 68 M 1 2 N N N N N TUR.BCG pTa,G2,6in 60< A
15 44 M 1 2 N N N N N TUR No 60< A
16 75 M A 1 N N N N N TUR pTa,Gl,22m 60< A
17 83 M 2< 2<3 N H N H FI TUR.rad No 21 D
18 99 M A l< 2 N N N N N TUR,BCG,Cx pTa,4m 60< A
19 81 M 2 2 N N N N H TUR Invasive 6 D
20 68 M 3 3 H H II H H TUR,rad Invasive 2 D
21 49 M 1 1<2 N N N N N TUR,BCG,Cx pTa,4m 60< A
22 71 M 1 2 N N N N N TUR, MMC No 60< A
23 53 M 2 3 H H H H H TUR, chemo Invasive 7 D
24 47 M 1 1 N N N N N TUR,chemo pTa,Gl,16m 60< A
25 79 M 2 3 H H H H ( - ) Cx Cx 4 D
26 72 M A 1 N N N N N TUR No 60< A
27 79 M 2 < 3 N N N N H TUR,Cx Invasive 10 D
28 76 F 3 2,SCC H H II N H TUR,Cx,rad Invasive 32 D
29 85 M 1 2 N N N N N TUR, MMC, ureterostomy pTa 49 D
30 68 M A 1<2 N N N N N TUR,MMC No 60-< A
31 62 F 2< 3 H H H N N TUR,chemo,rad No 20 D
32 50 F 3 2,SCC H H H N H TUR Invasive 5 D
33 75 M 3B 3 N N N H N TUR,rad,Cx Invasive 60< A
34 66 M A 2<3 N N N N N TUR, Cx,rad, chemo pTa,G2,8m 23 D
35 53 M 1 2 N N N N N TUR.BCG No 60< A
36 49 M 2 2<3 N N N N N TUR.rad, iridium Invasive 60< A
37 68 F 1 2 N N N N N TUR,MMC,BCG pTa,G2,6m 58 A
38 44 F 4 3 N N N N N TUR.Cx Invasive 29 D
39 65 M 1 1<2 N N N N N TUR pTl,G2,4m 51 A
40 62 M A 1 H N H H H TUR No 60< A
41 64 M 2< 3 H H H H H TUR.chemo.rad No 60< A
42 61 M 2< 3 H H H H H TUR,chemo,rad Invasive 15 D
43 73 M 2 2 N N N N N TUR.chemo.Cx Invasive 8 D
44 59 M 2< 3 H H H N H TUR.rad Invasive 3 D
45 47 M 2 3 H H H H H TUR, chemo Invasive 8 D
46 70 F 3B 2 N N H I-I N Cx Invasive 53 A
47 74 M 3 3 H H ( - ) H H Cx, chemo Cx 10 D
48 66 M A 2 N N N N N TUR,Cx pTa,G2,12m 60< A
“ SCC, squamous cell carcinoma. 
b E~cad, E-cadherin; N, normal; H, heterogenous; (- 
c TUR, transurethral resection; Cx, cystectomy; rad, 
{i A, alive; D, dead.
■), negative.
irradiation; chemo, systemic chemotherapy; MMC, Mitomycin; BCG, Bacillus CoulnwUe Guerin.
plete absence of immunoreactivity) and heterogeneous (i.e., tumor composed 
of positive and negative areas), as described previously (9).
One of the serial sections was stained with H&E for histological evaluation. 
The grading and staging of the tumor were based on WHO classification (17) 
and TNM classification of International Union Against Cancer (18), respec­
tively. Correlations among cadherin/catenin expression and tumor grade or 
stage were evaluated by x 2 test. Differences in survival were assessed by 
log-rank test. To evaluate clinical relevancy, the proportional hazard regression 
procedure supported by Statistical Analysis System was used.
RESULTS
In normal urothelium, catenin staining outlines the intercellular 
borders. The luminal membrane and the parts of the cells in contact 
with the basement membrane do not react with the antibodies (Fig. 
1 A, D, G, and J). A more pronounced staining at the apical junctional 
complexes of the superficial cell layer can be seen. The protein 
pl20tv,,y follows the same staining pattern as catenins. These patterns 
of staining are very similar to those observed with E-cadherin (Ref. 
14; Fig. 1M).
Detailed results for each tumor are given in Table 1. As previously 
found for E-cadherin* the most prevalent abnormal staining is not a 
complete absence of catenin expression but a heterogeneous immu­
noreactivity. Normal staining was found in 30 cases for a-catenin, 29 
cases for /3-catenin, 28 cases for y-catenin, 30 cases for p l20Crt‘\  and 
26 cases for E-cadherin. Overall, a good correlation was found be­
tween E-cadherin expression and the expression of each catenin (Fig. 
1B -0  except for D, G, Jt and M), However, in 10 cases, discrepancies 
were noticed. This included heterogeneous E-cadherin staining with 
normal staining for one or several catenin(s) in seven cases (cases 1,
2, 4, 17, 19, 27, and 40 in Table I), and normal E-cadherin staining 
with heterogeneous staining for at least one catenin in three cases 
(cases 13, 31, and 46 in Table 1). Discrepancies between E-cadherin 
expression and that of p l2 0 c"‘r were more frequent.
Correlations between the staining pattern for each antigen studied 
and the classical pathological data (grade and stage) are detailed in 
Table 2. As already shown for E-cadherin, a strong inverse correlation 
was found between immunoreactivity for members of the E-cadherin 
complex and both grade and stage.
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Fig. 1. Expression of a-catenin (A, B, and C), 
|3-catenin (D, E, and F), y-catenin (G, H, and /), 
pl20C£W (J, K, and L), and E-cadherin (M, N, and 0) 
in normal urothelium and bladder cancers. Original 
magnification, X400. In normal urothelium, a-cate- 
nin (A), ^-catenin (D), y-catenin (G), p l20CiiS (J), 
and E-cadherin (M) stainings outline the intercellular 
borders, with the luminal membrane of the superfi­
cial cells being devoid of staining. Note the pro­
nounced staining right below the luminal surface, 
which corresponds to the apical junctional complex. 
E-cadherin staining has been repeatedly found 
weaker than eaten in and pl20C£W staining in normal 
ureter. In a tumor with a normal staining pattern, 
a-catenin (£), /3-catenin (E), y-catenin (H), p l20cai 
(X), and E-cadherin (AO expression is preserved at 
the intercellular borders. In heterogeneous tumors, 
some tumor cells show distinct expression of a-cate- 
nin (C), /3-catenin (F), y-catenin (/), pl20cay (L), and 
E-cadherin (0 ) at intercellular borders, whereas 
other areas are negative.
Table 2 Comparison o f E-cadherin and catenin expression with stage (superficial
versus invasive) and grade (WHO classification)
Stage Grade
P ** P
a-catenin 14.7 <0.0001 16.2 <0.0003
ß -catenin 21.6 <0.0001 19,2 <0.0001
y-catenin 18.5 <0.0001 11.9 <0.0026
pl20CflJ 14.7 <0.0001 16.2 <0.0003
E-cadherin 18.5 <0.0001 13.0 <0.0015
Survival analysis showed that reduced expression of all of the 
antigens studied here correlates with poor survival (Table 3). Actu­
ally, the survival curves for E-cadherin and each of its associated 
molecules are very similar (Fig. 2). However, after stratification by 
stage, only E-cadherin remained a significant prognostic factor for 
patients with invasive disease. In this group of patients, decreased 
expression of a- and j3~catenin is associated with poor survival, but 
without reaching the classical 5% significance threshold. Importantly, 
no association between survival and plakoglobin or pl2Qcas expres­
sion was found in this group (Table 3). Within the patients with 
superficial disease, no correlation was found between survival and 
expression of any of the molecules of the adhesion complex. Propor­
tional hazard regression confirmed that /3-catenin, E-cadherin, and
a-catenin have a strong predictive value, similar to grade and stage. 
Plakoglobin and pl206™ staining have a somewhat lower predictive 
value (Table 4).
DISCUSSION
It has now become clear that the loss of E-cadherin-mediated 
adhesion is associated with the progression of many carcinomas. 
Accordingly, in v itro , E-cadherin has been shown to suppress the 
invasive potential of malignant cells (19, 20). We found previously 
that decreased E-cadherin expression correlates with poor prognosis 
for patients with bladder cancer (9). Because proper anchorage to the 
cytoskeleton is necessary for E-cadherin function, a lack of expression
Table 3 Correlation o f  E-cadherin and catenin expression with survival (log-rank test)
All tumors Invasive tumors
Variables x2 P *2 Pa
a-catenin 16.3 0.0001 2.1 NS
/3-catenin 26.1 0.0001 2.2 NS
y-catcnin 12.6 0.0004 0.57 NS
pl20C£W 6.8 0.009 0.02 NS
E-cadheri n 17.0 0.0001 4.21 0.02-0.05
a NS, not significant.
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Fig. 2. Kaplan-Meier survival curves according 
to (he staining for E-cadherin 04, B), a-catenin (C, 
D), and j3-catenin (E, F). Left column, analysis on 
the whole group, showing significant differences 
in survival (A, C, and E). Right column, analysis 
restricted to patients with invasive tumors; pa­
tients with normal staining have better survival, 
however, the difference is significant only for 
E-cadherin (B, D, and F).
survival
rate
1.0
0.8
0.6
0.4
0.2
0,0
\
p<0.01
H
H
L-Ll___ U
normal (n=26)
J
abnormal (n=22)
X
survival 
rate .
1.0
0.8
0.6
0.4
0.2
20 40 60 , 80 
months
0,00 20
D
40
0.02 < p <0.05
i j
normal (n=7)
abnormal (n=19)
60 80 
months
or defect of the molecules involved in this anchorage can. also be 
responsible for cancer cell invasion. We thus studied catenin 
expression and compared it with E-cadherin expression to deter­
mine what specific prognostic information can be obtained from 
each antigen. We show that in bladder tumors, decreased expres­
sion of each catenin, including p l20c"‘\  is significantly correlated 
with poor prognosis.
It has been suggested that in esophageal cancer, a-catenin is 
better correlated with invasion and metastasis than is E-cadherin 
(13). Our proportional hazard regression analysis does not confirm 
this for bladder tumors. Actually, we found that /3-catenin, E- 
cadherin, and a-catenin have very similar prognostic values. Thus,
Table 4 Comparison o f the prognostic value o f tumor stage, grade, and cell adhesion 
protein expression using the proportional hazard regression analysis for survival
Variable X2 score P
Stage 20.9 0.0001
Grade 15.4 0.0001
a-catenin 16.9 0.0001
j3-catenin 27.0 0.0001
y~ eaten in 13.0 0.0003
p 120cas 7.0 0.008
E-cadherin 17.4 0.0001
any of these molecules can be used in practice to assess bladder 
tumor prognosis. The clinical potential of this study is demon­
strated by the correlation we have found between these three 
parameters and survival in the subgroup of patients with invasive 
disease. This correlation is significant for E-cadherin, whereas P 
does not reach the classical 5%  significance threshold for j3- and 
a-catenin. In patients with superficial disease, no correlation was 
found, probably because most superficial bladder tumors are not 
life-threatening. Correlation with progression would be more rel­
evant here, but it is difficult to study because it requires a large 
number of patients to obtain adequate numbers of end points. 
However, the prognostic value of plakoglobin and p l2 0 ta'v is 
clearly lower.
In seven cases, heterogeneous staining for E-cadherin was found, 
whereas a-, ¡ 3 and y-catenins seemed normally expressed (although 
the evaluation of intercellular border staining on frozen sections may 
be difficult in some cases). Because it has been demonstrated that both 
plakoglobin and a-catenin are unstable in L cells lacking cadherin, 
and that they can be stabilized by either desmosomal cadherins or 
E-cadherin, respectively (21, 22), the staining pattern found in these 
seven cases might indicate that catenins are stabilized by molecules 
other than E-cadherin. Actually, we have evidence that in mode]
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systems, other members of the classical cadherin family can form a 
complex with catenins.3 However, the role of these cadherins in 
epithelial differentiation and cancer progression is not yet clear.
In three cases, the opposite observation was made; E-cadherin 
staining was normal, whereas catenin immunoreactivity indicated that 
no functional complexes were present. In these cases, one can assume 
that although E-cadherin is stably expressed, it does not form a 
functional complex, and that the primary molecular lesion is not 
decreased E-cadherin expression but instead, either decreased catenin 
expression or expression of nonfunctional (mutated) molecules.
The correlation between E-cadherin expression and p l2 0 cas is not 
as tight as the correlation between E-cadherin and catenin expression. 
Actually, very little is known about p l2 0 cai'. In particular, its function 
in the E-cadherin complex is not yet well understood. Recently, it has 
been shown that p i20™* can interact with E-cadherin but not a-cate­
nin (23). Thus, p l20C£W does not occupy a place similar to its structural 
homologues plakoglobin and /3-catenin that bridge E-cadherin to 
a-catenin.
In conclusion, we have compared the prognostic value of the 
expression of several catenins with that of E-cadherin in bladder 
tumors. Although a-catenin has been studied in several cancers, data 
on the expression of /3-catenin, plakoglobin, and p \2 0 cas were previ­
ously missing. To our knowledge, this is the first report correlating 
catenin expression to survival. Interestingly, we have found that 
/3-catenin, E-cadherin, and a-catenin have a similar prognostic values. 
Thus, from a practical point of view, staining for any of these antigens 
can be used as a prognostic indicator. This is of particular interest 
because it seems difficult to obtain reliable E-cadherin staining on 
routinely processed (formalin-fixed, paraffin-embedded) samples4 
(15, 24), indicating that staining for catenins may be a more reliable 
diagnostic tool.
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